Cosentyx Denied by Insurance?
How to Appeal & Get Approved
Generic: secukinumab
A leading IL-17 inhibitor for psoriasis and psoriatic arthritis — with competitive formulary battles.
- Used for
- Psoriatic Arthritis, Ankylosing Spondylitis
- Route
- IV
- Specialty
- Rheumatology
- PA Required
- Yes — 89% of prescriptions
Common Denial Reasons
Cosentyx is frequently denied for step therapy, documentation, and formulary reasons. Decode your specific denial →
require prior authorization before your pharmacy can fill them. If you've been denied, you're not alone — and most denials can be overturned on appeal.
Step Therapy Requirements
"Fail first" — what insurers require before approving Cosentyx
Most insurers require you to try alternative medications before approving Cosentyx. See your insurer's requirements →
Let Ellen Fight Your Cosentyx Denial
Ellen generates a personalized appeal letter for Cosentyx using your denial reason, insurer, and clinical situation.
- ✓Instant denial decoding — understand why you were denied
- ✓Payer-specific appeal language that matches your insurer's criteria
- ✓Clinical evidence suggestions your doctor can use
Insurance Coverage
Ellen tracks Cosentyx coverage across 32+ major insurers including formulary status, step therapy requirements, and common denial patterns.
Check your insurer's Cosentyxpolicy →Safety Information
From FDA-approved prescribing information for Cosentyx (IL-17A Inhibitor)
Do Not Use If
- ✕Clinically significant hypersensitivity to secukinumab
Key Warnings
- ⚠May worsen inflammatory bowel disease — monitor for new onset or exacerbation of Crohn's/UC
- ⚠Evaluate for TB before starting
- ⚠Increased risk of infections
This is not a complete list. See the full Cosentyx prescribing information or ask your pharmacist for comprehensive safety data.
Frequently Asked Questions
›Is Cosentyx or Skyrizi preferred by insurance?
It varies by plan. Some formularies prefer Cosentyx (IL-17), others prefer Skyrizi (IL-23). If your plan denies one, ask your dermatologist about the preferred alternative or appeal with clinical justification.
›What step therapy is required for Cosentyx?
For psoriasis: failure of conventional systemic therapy and meeting BSA thresholds. For PsA and AS: many plans require TNF inhibitor failure first, though guidelines support IL-17 as a first-line biologic option.
›How do I appeal a Cosentyx denial for psoriatic arthritis?
Document DMARD failures, disease activity scores (DAPSA, minimal disease activity criteria), and joint damage progression. If TNF inhibitors are contraindicated (e.g., IBD history — TNF inhibitors can worsen IBD), document this clearly.